Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 1998, p. 1923-1930, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Ciprofloxacin Induces an Immunomodulatory
Stress Response in Human T Lymphocytes
Kristian
Riesbeck,*
Arne
Forsgren,
Agnethe
Henriksson, and
Anders
Bredberg
Department of Medical Microbiology, Lund
University, Malmö University Hospital, S-205 02 Malmö,
Sweden
Received 9 February 1998/Returned for modification 13 May
1998/Accepted 3 June 1998
 |
ABSTRACT |
Exposure of cells to adverse environmental conditions invokes a
genetically programmed series of events resulting in the induction of
specific genes. The fluoroquinolone antibiotic ciprofloxacin has
recently been reported to upregulate interleukin-2 (IL-2) gene
induction. In the present investigation, the effect of ciprofloxacin at
supratherapeutic concentrations on immediate-early (<2 h) gene expression in primary human peripheral blood lymphocytes was studied with Northern blots. In addition, transcriptional activity of IL-2 and
metallothionein enhancer and promoter regions and transcription factors
AP-1, NF-
B, and NF-AT were analyzed by chloramphenicol acetyltransferase (CAT) and electrophoretic mobility shift assays, respectively. The concentration of c-fos,
c-jun, c-myc, junB, and
fra-1 mRNAs was increased in activated peripheral blood
lymphocytes incubated with ciprofloxacin compared to that in untreated
controls. Ciprofloxacin increased CAT activity in stimulated
lymphocytes transfected with plasmids containing either the IL-2 or
metallothionein enhancer. Furthermore, among the transcription factors
tested, AP-1 activity was increased in stimulated purified T helper
lymphocytes incubated with ciprofloxacin compared to drug-free
controls. Taken together, ciprofloxacin increased the levels of
immediate-early transcripts, enhanced IL-2 and metallothionein promoter
induction, and upregulated AP-1 concentrations in primary lymphocytes,
reflecting a program commonly observed in mammalian stress responses.
 |
INTRODUCTION |
Fluoroquinolones, which perform
their bactericidal effect by inhibiting DNA gyrase (a type II
topoisomerase) (5), are known to interfere with certain
immune functions. Ciprofloxacin and other quinolones at >20 µg/ml
inhibit peripheral blood lymphocyte (PBL) cell growth by 30 to 35%,
causing impaired cell cycle progression through the S phase
(8). Cell cycle analysis thus indicates DNA synthesis to be
inhibited by fluoroquinolones at these concentrations. Despite this
adverse effect on cell growth, fluoroquinolone antibiotics at
therapeutic concentrations (between 1.56 and 6.25 µg/ml) are able to
enhance [3H]thymidine incorporation two- to threefold in
phytohemagglutinin (PHA)-stimulated PBLs, compared to that in control
cells unexposed to antibiotics, the effects being most pronounced after
4 to 5 days of lymphocyte incubation (8, 38).
In addition to the stimulatory effects on thymidine incorporation,
ciprofloxacin (range, 5 to 80 µg/ml) and other fluoroquinolones potentiate interleukin-2 (IL-2) synthesis by PHA-stimulated PBLs (26, 42). Experiments with the human T-cell lymphoma cell line Jurkat and the murine equivalent EL-4, transiently transfected with a plasmid containing the IL-2 promoter region, show that ciprofloxacin enhances IL-2 promoter activation (27, 30). An
earlier and stronger ciprofloxacin-dependent activation of the
transcriptional regulation factors nuclear factor of activated T cells
1 (NF-AT-1) and activator protein 1 (AP-1) is observed in these
immortalized cell lines. In accordance with these findings, under
certain in vitro conditions, ciprofloxacin (20 to 80 µg/ml) counteracts the effect of the immunosuppressive agent cyclosporine A
that normally inhibits the phosphatase activity of calcineurin, causing
impaired NF-AT-1 activity (29). Ciprofloxacin thus
interferes with a regulative pathway common to several cytokines.
Indeed, analysis of cytokine mRNAs in ciprofloxacin (20 to 80 µg/ml)-treated PBLs revealed that not only IL-2 mRNA is enhanced but
so are an array of other cytokine mRNAs, including gamma interferon
(IFN-
) and IL-4 (30). Finally, there are several reports
on ciprofloxacin-dependent immunomodulation in vivo, strongly
indicating that the cytokine upregulation observed is not an in vitro
artifact (19, 36, 38, 41).
Exposure of cells to DNA-damaging agents induces numerous genes that
facilitate the repair of such lesions. This response is essential for
an organism to adapt to life-threatening environmental conditions and
to duplicate its genetic material with the highest fidelity. This
sensory network has been thoroughly characterized in bacteria.
Treatment of Escherichia coli with agents that damage DNA or
inhibit replication (for example, quinolone antibacterials) induces a
set of physiological responses that have collectively been called the
SOS response (40). These responses promote cell survival,
and blocking them genetically leads to DNA damage sensitivity. Numerous
genes that are transcriptionally activated in response to DNA damage
have been identified, including several involved in excision repair,
recombinational repair, SOS repression, mutagenesis, and cell cycle
arrest.
In eukaryotic cells, a network of overlapping systems seems to be
activated following exposure to DNA-damaging agents. Many genes are
induced specifically by UV and gamma rays, while others also respond to
alkylating agents and to growth arrest (7, 10, 17). In
several cases, the cellular response to genotoxic treatment is
triggered by signal transduction pathways which are not DNA damage
specific (i.e., many of the genes triggered by DNA damage are also
induced by agents such as phorbol esters and by metabolic or oxidative
stress) (5, 10, 11, 34). The activation of primary
stress-inducible genes (e.g., the immediate-early expressed genes
c-fos, c-jun, and c-myc) is rapid and
independent of protein synthesis, whereas secondary induced genes
(e.g., early expressed cytokines and genes involved in DNA repair) are
expressed later and are dependent on the primary ones (10,
11).
The eukaryotic UV response is the most well-characterized
stress-induced pathway and resembles in many ways the bacterial SOS
response (7, 16). Following UV exposure, the
membrane-associated Src tyrosine kinases are induced, leading to
activation of cytoplasmic protein kinases that eventually increase AP-1
activity and induce nuclear translocation of NF-
B. The enhancement
in AP-1 activity is mediated both by induction of c-jun and
c-fos expression and by posttranslational modification of
c-Jun. The majority of genes identified during a UV response are not
specifically linked to DNA repair. However, the gene product of the UV-
and gamma-ray-inducible GADD45 gene stimulates excision
repair as well as inhibits DNA replication by blocking the cell cycle
at the G1 checkpoint (for a review, see reference
37). Metallothionein is another well-studied example
of a UV and DNA damage-inducible gene (15). Overexpression of metallothionein protects mammalian cells against oxidative stress
and can dramatically reduce the level of intracellular oxygen radicals
(35).
Topoisomerase II inhibitors have also been shown to trigger DNA damage
responses (20, 23, 31, 39). We have demonstrated that
ciprofloxacin at high concentrations (80 µg/ml) interferes with
topoisomerase II in human lymphoblastoid Raji cells (2). This phenomenon, in addition to the fact that IL-2 and other cytokines are enhanced in ciprofloxacin-treated cells (26, 30), led us
to examine whether ciprofloxacin induces a stress response in primary
human lymphoid cells. Surprisingly, ciprofloxacin superinduced both
IL-2 and metallothionein gene induction in PHA-activated PBLs compared
to that in untreated controls. Ciprofloxacin was also found to increase
the concentrations of immediate-early gene transcripts without
influencing mRNA stability. Finally, the transcription factor AP-1 was
strongly induced by ciprofloxacin, whereas binding of NF-AT-1 and
NF-
B was unaffected. Taken together, our data indicate that the
increased cytokine production observed in the presence of ciprofloxacin
is most likely related to a mammalian stress response.
 |
MATERIALS AND METHODS |
Reagents.
Preservative-free ciprofloxacin was kindly
provided by Bayer (Wuppertal, Germany). PHA (Wellcome, Dartford,
England) and phorbol myristate acetate (PMA; Sigma, Stockholm, Sweden)
were dissolved in RPMI 1640 medium and dimethylsulfoxide, respectively.
Actinomycin D was purchased from Boehringer Mannheim (Mannheim,
Germany) and used at a final concentration of 10 µg/ml.
Cells.
Human PBLs were isolated from buffy coats with
citrate or from heparinized blood from healthy donors by centrifugation
on a step gradient of Ficoll-Isopaque (Lymphoprep; Pharmacia, Uppsala, Sweden) (26). PBLs (106/ml) were incubated in a
humidified 5% CO2 atmosphere in RPMI 1640 medium
containing HEPES buffer (Gibco, Paisley, Scotland) supplemented with
10% heat-inactivated fetal calf serum, glutamine, and gentamicin (12 µg/ml). A pure population (>98%) of CD4+ T cells was
isolated with Dynabeads (Dynal, Oslo, Norway). A protocol consisting of
a negative selection procedure was used based upon the manufacturer's
instructions. The biological activity of IL-2 in supernatants was
analyzed by means of IL-2-dependent stimulation of proliferation of the
murine cytolytic T-lymphocyte line CTLL-2 as previously described
(26).
RNA isolation, Northern blots, and DNA.
Total RNA was
prepared as previously reported (30). RNA (10 to 20 µg)
was loaded onto formaldehyde-agarose gels and blotted to nylon filters
(Hybond-N+; Amersham, Buckinghamshire, England) as
described by the manufacturer. Filters were hybridized according to
standard protocols and exposed for 24 to 72 h to preflashed X-ray
film (XAR-5; Kodak, Rochester, N.Y.) at
70°C by using intensifying
screens. Autoradiographs were quantified by scanning laser
densitometry. The gene-specific probes used to probe RNA blots were
isolated from agarose gels after digestion of the plasmids in which
they were propagated with the appropriate restriction endonucleases.
The c-myc probe was a 1,000-bp
ClaI-EcoRI fragment isolated from a human
c-myc cDNA. The fra-1 cDNA was a 900-bp
EcoRI fragment from pfraI (1). The
c-fos probe was a 900-bp ScaI-NcoI
fragment from pc-fos-1 (American Type Culture Collection),
and the c-jun probe was an
1,400-bp
NotI-HindIII fragment from
pRSV-c-jun (provided by Michael Karin) (9). The
junB probe (murine) was a 1,800-bp EcoRI fragment from pjunB (1). The fra-1,
junB, and c-myc cDNAs were kindly provided by T. Lindsten. The IL-2- and IFN-
-specific probes and
-actin cDNA have
been described previously (30). DNA fragments were labeled
with [
-32P]dCTP (specific activity 3,000 Ci/mmol; PB
10205; Amersham) by random priming (Amersham). Free nucleotides were
separated on spin columns (Costar, Cambridge, Mass.) containing
Sephadex G-50 fine (Pharmacia). For transfection experiments,
expression vectors MT-CAT-SV and SV-IL-2-CAT were used (reference
30 and references therein). DNA concentrations were
estimated by DNA dipstick (Invitrogen, San Diego, Calif.) or by
examination on agarose gels.
Transfections and CAT assay.
PBLs were stimulated in the
presence of PHA (1 µg/ml) and PMA (50 ng/ml) for 18 h before
transfection by electroporation with a Gene Pulser apparatus (Bio-Rad,
Richmond, Calif.). Before transfection, cells in log phase were washed
in Tris-buffered saline. For each electroporation, 107
cells were resuspended in 350 µl of serum-free medium and transferred to a 1-ml electroporation cuvette with a 0.4-cm space between the
electrodes (Bio-Rad). After addition of 10 µg of the appropriate plasmid DNA, the samples were gently shaken and kept at room
temperature for 5 min. The samples were subjected to electroporation at
960 µF and 450 V. The pulse generated an exponential decay pulse with time constants at 36 to 43 ms. In all experiments, cells were mixed
after the transfections and aliquoted to different culture flasks.
Cells were rested for 36 h followed by addition of ciprofloxacin and 1 µg of PHA per ml. After activation for 15 h, cells were washed, extracts were prepared, and the chloramphenicol
acetyltransferase (CAT) reaction, including separation of products by
thin-layer chromatography, was performed as previously reported
(30). No CAT activity was detected in untransfected cells
with or without ciprofloxacin.
Electrophoretic mobility shift assay.
Whole-cell protein
extracts were prepared from stimulated CD4+ T cells
(33), and protein concentrations were determined with a
commercial protein assay (Pierce bicinchoninic acid reagent; Tecator,
Sollentuna, Sweden). Protein extract (3.5 to 5.0 µg/reaction) was
mixed with 1.0 µg of poly(dI-dC) (Boehringer Mannheim) and 5×
binding buffer (100 mM phosphate buffer [pH 6.0], 50 mM
MgCl2, 0.5 mM EDTA, 10 mM dithiothreitol, 0.05% Nonidet
P-40, 0.5 M NaCl, 500 µg of bovine serum albumin per ml, 20% Ficoll)
in a final volume of 15 µl. After incubation for 10 min at room
temperature, a 10,000- or 15,000-cpm 32P-kinased probe
(60 × 10
6 to 90 × 10
6 µg) was
added, and the reaction mixtures were incubated for a further 20 min at
37°C. Samples were separated by 5% Tris-borate-EDTA-polyacrylamide gel electrophoresis (PAGE) were fixed, dried, and autoradiographed. The
probes used were the AP-1 consensus binding site
(5'-ctagtgatgagtcagccggatc-3'), an Oct-1 binding site
(5'-cgtctcatgcgatgcaaatcacttgagatc-3'), an NF-
B consensus
binding site (5'-gatcgaggggactttccctagc-3'), and, finally,
an NF-AT-1 binding sequence (5'-ggaggaaaaactgtttcatacagaaggcgt-3') (30). Competition experiments with 10 to 1,000× molar
excess of unlabeled oligonucleotides were carried out to identify the specific complexes. For supershift analyses, polyclonal antibodies (1 µg/reaction) directed against the c-Fos family (K-25), c-Fos (4-G),
Fra-1 (N-17), the c-Jun family (D), c-Jun/AP-1 (N), JunB (210), and
JunD (329) were used. All antibodies were purchased as gel supershift
reagents from Santa Cruz Biotechnology (Santa Cruz, Calif.). Rabbit
immunoglobulin was used as a negative control (Dakopatts, Gentofte,
Denmark).
Statistics.
Student's t test for paired data was
used for statistical calculations. Statistical significance was set at
P
0.05.
 |
RESULTS |
Superinduced early gene transcription by ciprofloxacin in primary
lymphocytes.
We have earlier demonstrated that ciprofloxacin
enhances several cytokine mRNAs, including IL-2 and IFN-
in
PHA-activated PBLs incubated for 24 to 72 h (30). In
order to characterize the early kinetics of IL-2 and IFN-
transcripts, total RNA was isolated from PHA-activated PBLs incubated
with ciprofloxacin for up to 10 h. Specific cytokine mRNAs in
addition to the housekeeping
-actin message were analyzed with
Northern blots with radioactive cDNA probes. At 4 to 10 h of
culture, IL-2 and IFN-
mRNA levels were significantly increased in
PBLs incubated with ciprofloxacin compared to in untreated controls. Up
to 2.2-fold-more IL-2 mRNA was detected in ciprofloxacin-treated cells
as early as 6 h after PHA activation (Fig.
1A). A similar increase was observed when IFN-
mRNA was examined (Fig. 1B). The ciprofloxacin-dependent superinduction of cytokine mRNAs resulted in enhanced cytokine secretion (Fig. 1C). In PBL cultures incubated with ciprofloxacin, the
IL-2 and IFN-
production increased 10- and 4-fold, respectively.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of IL-2 and IFN- gene expression in PBLs
exposed to ciprofloxacin. IL-2 (A) and IFN- (B) mRNA concentrations
were analyzed at 30 min to 10 h for human PHA-activated PBLs
incubated with ciprofloxacin (80 µg/ml) ( ) and compared to those
in drug-free controls ( ). At 24 h, IL-2 and IFN-
concentrations (C) in culture supernatants were analyzed. Total RNA was
isolated at the indicated time points, and Northern blotting was
performed with comparable samples of RNA. Radioactive cDNA probes
specific for the indicated genes were sequentially hybridized to the
filters. Scanning densitometry data are shown. The specific cytokine
values were divided by the corresponding values for -actin mRNA. An
arbitrary unit was defined as equal amounts of cytokine mRNA and
-actin mRNA. No cytokine mRNA was detected in unstimulated PBLs at
time zero and was set as 0 arbitrary units. The data presented in
panels A and B are representative of three independent experiments and
blood donors. (C) IL-2 and IFN- were analyzed with an IL-2-dependent
cytotoxic T-cell line and enzyme-linked immunosorbent assay,
respectively. Results from four separate experiments are shown. Error
bars in panel C indicate the standard deviation. P < 0.01 and P < 0.001 for IL-2 and IFN- ,
respectively.
|
|
Collective data from our previous investigations demonstrated that
ciprofloxacin enhances IL-2 transcriptional activity in
T cells
(
27,
30). However, those studies were performed with
immortalized cell lines that in many ways differ from primary
cells. To
characterize gene transcription in ciprofloxacin-treated
primary
lymphocytes, human PBLs were transiently transfected with
a construct
containing the IL-2 promoter and enhancer in conjunction
with a simian
virus 40 (SV40) enhancer element linked to the bacterial
reporter gene
coding for CAT. In addition, a CAT plasmid consisting
of the
metallothionein enhancer and promoter (instead of the corresponding
part of IL-2) was used as a control. IL-2 promoter activity was
enhanced (i.e., an increased CAT activity was detected in PBLs
incubated in the presence of ciprofloxacin at 80 µg/ml) (Fig.
2A). Interestingly, when metallothionein
enhancer activity was
examined in ciprofloxacin-treated PBLs, CAT
activity was found
to be upregulated. Metallothionein expression in
PHA-activated
PBLs increased 2.2- and 4.3-fold at ciprofloxacin
concentrations
of 40 and 80 µg/ml, respectively, compared to that in
controls
without ciprofloxacin (Fig.
2B). The superinduced
metallothionein
gene activity was considerably stronger than the IL-2
gene induction.
For comparison, ciprofloxacin at 40 and 80 µg/ml
increased IL-2
gene induction 1.3- and 2.1-fold, respectively. Thus,
the augmented
gene transcription by ciprofloxacin was not specific for
lymphocyte-derived
cytokines.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 2.
Ciprofloxacin-dependent increase of IL-2 and
metallothionein enhancer and promoter regions in stimulated PBLs. Raw
data are shown for IL-2 and metallothionein, indicated by SV-IL-2-CAT
and MT-CAT-SV, respectively (A). Relative CAT activities for
ciprofloxacin-treated PBL are also presented (B). PBLs were stimulated
(1 µg of PHA per ml and 50 ng of PMA per ml) for 18 h, at which
time, cells were transfected with the indicated plasmids and rested.
After 36 h, PBLs were rechallenged with 1 µg of PHA per ml and
incubated with or without ciprofloxacin (40 or 80 µg/ml). After an
additional 15 h, cells were lysed and CAT activity was analyzed as
described in Materials and Methods. For quantification, areas
containing the acetylated and nonacetylated forms of chloramphenicol
were cut out from thin-layer chromatography plates and measured with a
scintillation counter. Six independent donors were examined on six
different occasions. Duplicates were included in all experiments. Error
bars indicate the standard error of the mean. Values for
ciprofloxacin-treated PBLs were significantly different from those of
the controls. SV-IL-2-CAT, P < 0.05 and
P < 0.01 for ciprofloxacin at 40 and 80 µg/ml,
respectively. MT-CAT-SV, P < 0.001 and
P < 0.05 for ciprofloxacin at 40 and 80 µg/ml,
respectively.
|
|
Effect of ciprofloxacin on transcription factor activity in primary
lymphocytes.
Since ciprofloxacin has been shown to interfere with
transcription factors in the two T-cell lymphoma cell lines Jurkat and EL-4 (27, 30), the next step was to examine the
transcription factors AP-1, NF-AT-1, and NF-
B in T cells purified
from peripheral blood. To exclude monocytes and B lymphocytes,
CD3+ CD4+ lymphocytes (T helper cells) were
isolated by negative selection with magnetic beads. Total cell protein
was isolated from PHA- and PMA-activated CD4+ T cells at 1 to 4 h and incubated with a 32P-labelled
oligonucleotide corresponding to an AP-1 consensus binding site. When
the protein-DNA complexes were analyzed by PAGE, a distinct pattern
appeared (Fig. 3A). At
3 h of
incubation, a higher level of AP-1 binding was detected in
CD4+ T-cell extracts purified from activated cells
incubated with ciprofloxacin compared to that in drug-free controls. To
verify that equal amounts of protein were added to the reaction
mixtures, cell extracts were also analyzed for Oct-1 binding that is
considered to be invariable during the cell cycle (not shown). Mean
AP-1 binding activities divided by corresponding values for Oct-1 are illustrated in Fig. 3B. In contrast, when the same cell extracts were
examined for NF-AT-1 or NF-
B binding, we did not observe any
difference between ciprofloxacin-treated cells and controls incubated
without any drug (data not shown).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 3.
Increased AP-1 binding activity in stimulated
CD4+ T cells incubated with ciprofloxacin. A typical AP-1
shift is shown for activated purified T helper cells incubated with
( ) or without ( )) ciprofloxacin (80 µg/ml) (A). Scanning
densitometry data from three independent experiments are also shown
(B). Total cell protein was isolated from a pure population of T helper
cells that had been activated with PHA (1 µg/ml) and PMA (50 ng/ml)
for the indicated times. Protein extracts were incubated with
radioactive oligonucleotides and analyzed by PAGE. n.p., a reaction
without any protein. In panel B, 1 arbitrary unit was defined as equal
amounts of AP-1 and Oct-1. No AP-1 binding activity was detected in
unstimulated cells incubated with ciprofloxacin.
|
|
To further characterize the different proteins included in the AP-1
complex detected in T cells exposed to ciprofloxacin,
supershifts were
performed. The reaction mixtures were supplemented
with polyclonal
antibodies directed against the specific members
of the c-Fos and c-Jun
families 30 min prior to addition of the
radioactive AP-1
oligonucleotide. Cytoplasmic protein isolated
from the 3-h time point
with ciprofloxacin, as shown in Fig.
3A,
was analyzed for AP-1 components. The upper band showed the specific
AP-1 binding, as can be seen in Fig.
4,
lane 1. The AP-1 shift
disappeared when the polyclonal antiserum
against the c-Fos and
c-Jun family of proteins was added, as
illustrated in lane 2 (pan-c-Fos)
and lane 6 (pan-c-Jun), respectively.
Rabbit immunoglobulin, a
negative antibody control, did not interfere
with the specific
AP-1 band (Fig.
4, lane 10). Interestingly, the AP-1
complex mainly
consisted of the FosB, JunB, and JunD proteins. A
similar pattern,
however, was seen in ciprofloxacin-free control
extracts. Taken
together, the upregulated AP-1 activity observed in
ciprofloxacin-treated
T cells was indeed specific because it consisted
of proteins from
the c-Fos and c-Jun families.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 4.
The superinduced AP-1 complex in ciprofloxacin-treated
CD4+ T cells contained proteins from the c-Fos and c-Jun
families. Cell extract from the CD4+ T cells exposed to
ciprofloxacin for 3 h displayed in Fig. 3A was examined in
supershifts. The upper band shows the specific AP-1 binding (see, for
example, lanes 1 and 3). The lower band shows the unspecific binding to
the AP-1 oligonucleotide sometimes observed. Rabbit polyclonal
antibodies were preincubated with the extracts for 30 min on ice prior
to addition of the AP-1 oligonucleotide. Unspecific rabbit
immunoglobulins, which were used as a control serum, are indicated by
rabbit immunoglobulin G (IgG) in lane 10. The free probe (shown in Fig.
3A) was run out from the gel. Similar results were obtained with the
2-h extract from control T cells shown in Fig. 3A (data not presented).
The results are representative for two different blood donors.
|
|
Increased concentrations of immediate-early expressed mRNAs in
ciprofloxacin-treated PBLs.
Metallothioneins that protect cells
against oxidative stress are induced by a wide range of different
stimuli, including metals and UV C radiation (14). The
observed hyperinduced metallothionein transcription in addition to
increased AP-1 activity suggested that a phenomenon similar to a stress
response occurred in PBLs incubated with ciprofloxacin. This urged us
to examine the expression of c-fos, c-jun, and
c-myc mRNAs, which is commonly related to mammalian stress
responses. To investigate the effect of ciprofloxacin on these
immediate-early gene transcripts, PBLs were stimulated with PHA and
incubated with ciprofloxacin (80 µg/ml), followed by analysis of
steady-state mRNA levels at various time points. No major differences
were observed between ciprofloxacin-treated and control PBLs during the
first 20 min of culture (not shown). However, after 30 to 120 min of
incubation, more c-fos and c-jun mRNAs were
detected in cells incubated with ciprofloxacin than in drug-free
controls (Fig. 5A and B). The increased
mRNA levels found in cells incubated with ciprofloxacin were present up
to 10 h of incubation. After 4 h of incubation, ciprofloxacin
did not, however, enhance steady-state mRNA concentrations above the initial mRNA levels detected at 30 to 60 min. In contrast to
c-fos and c-jun mRNAs, c-myc mRNA was
expressed earlier in ciprofloxacin-treated PBLs (at 2 to 6 h) than
in the drug-free controls (Fig. 5C). Interestingly, the kinetics of
these immediate-early induced genes were in accordance with the
kinetics for IL-2 and IFN-
mRNAs, whose expression is dependent on,
among other proteins, c-Fos and c-Jun. The steady-state cytokine mRNA
levels increased at
4 h (Fig. 1A and B), a time point when the
immediate-early mRNAs already had started accumulating (Fig. 5). Thus,
in ciprofloxacin-treated cells, the activated AP-1 found at
2 h (Fig.
3B) paralleled the increased c-jun and c-fos mRNA
steady-state levels detected at
30 min.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 5.
Kinetics of immediate-early gene transcripts in
stimulated PBLs incubated with ciprofloxacin. Northern blot results are
shown for c-fos (A), c-jun (B), and
c-myc (C) mRNA expression between 30 min and 10 h with
( ) or without ( ) ciprofloxacin. PBLs were isolated from healthy
donors, and PHA (1 µg/ml) in addition to ciprofloxacin (80 µg/ml)
was added at culture initiation. Specific mRNAs were analyzed as
described in the legend to Fig. 1. One typical experiment out of three
is shown.
|
|
Ciprofloxacin did not stabilize the immediate-early expressed gene
transcripts.
To exclude whether ciprofloxacin influenced
c-fos, c-jun, and c-myc mRNA
degradation, ciprofloxacin with or without the transcriptional inhibitor actinomycin D was added to PBLs that had been stimulated with
PHA for 6 h. Different mRNAs were analyzed after 2 and 4 h of
the actinomycin D and/or ciprofloxacin chase (Fig.
6, lanes 7 to 12). Irrespective of the
presence or absence of ciprofloxacin, c-myc,
c-fos, c-jun, junB, fra-1,
and IL-2 mRNAs were all degraded in actinomycin D-treated cells (i.e.,
when new mRNA transcription was inhibited by actinomycin D). Thus,
ciprofloxacin did not influence the half-life of the immediate-early
transcripts. In the absence of actinomycin D, the various mRNAs were
found to be upregulated by ciprofloxacin after both 2 and 4 additional
h of culture, indicating that even a short exposure to the drug
resulted in increased mRNA concentrations (Fig. 6, lanes 1 to 6). For
example, 2.6- and 2.7-fold increases of c-jun and
junB mRNA levels, respectively, were detected after a 4-h
ciprofloxacin pulse. In contrast, the control mRNA,
-actin, was
unaffected by ciprofloxacin.

View larger version (79K):
[in this window]
[in a new window]
|
FIG. 6.
Ciprofloxacin does not influence the half-lives of
immediate-early gene transcripts in activated PBLs. Northern blot
results are shown for c-myc, c-fos,
c-jun, junB, and fra-1 mRNAs. For
comparison, IL-2 mRNA was included. Scanning densitometry data are
shown below the specific mRNA bands and were obtained by dividing all
values by the corresponding values for -actin mRNA. Control cell
cultures (without any addition of drugs) were set to 100 arbitrary
units for the different mRNAs. Lane numbers are indicated at the
bottom. Human PBLs were stimulated with PHA (4 µg/ml) for 6 h,
at which time ciprofloxacin (80 µg/ml) and/or actinomycin D (Act D
[10 µg/ml]) was added. mRNAs were analyzed at 0, 2, and 4 h of
additional lymphocyte incubation as described in the legend to Fig. 1.
The data presented are representative of three independent experiments
including different blood donors.
|
|
 |
DISCUSSION |
In the present investigation, we show that the quinolone
antibiotic ciprofloxacin induces a mammalian stress response similar to
the SOS response seen in bacteria. The extent to which the implications
of the effects of fluoroquinolones on PBLs observed in the present
study are of clinical interest is difficult to establish, since the
effects were observed at intermediate and high quinolone concentrations
not reached in patients. However, the most likely parallels can be
drawn with the effects of clinically achievable concentrations of
ciprofloxacin. It is well established that ciprofloxacin and other
quinolones at 5 µg/ml increase IL-2 production in both human and
murine in vitro systems, but also that a maximal effect is observed at
80 µg/ml (26, 38). Due to the relatively insensitive
methods presently available, we did not detect any IL-2 mRNA increase
at 5 µg/ml but only detected increases at 20 and 80 µg/ml
(30). In parallel, the augmented induction of the IL-2 and
metallothionein genes was observed at
40 µg/ml (Fig. 2). Recently
published reports on immunomodulatory effects of ciprofloxacin in vivo
support our hypothesis. For example, when ciprofloxacin at clinically
relevant doses was administered to sublethally irradiated mice,
hematopoiesis was stimulated, most probably due to induction of
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-3
(19, 36). Despite the high concentrations of ciprofloxacin
(80 µg/ml) that were required for us to sense a significant response
in vitro, augmented GM-CSF and IL-3 mRNA levels were observed in
mitogen-activated PBLs exposed to ciprofloxacin (30).
Another example of a relationship between in vitro and in vivo findings
was recently published by Wrishko et al. (41). In their
study, a pharmacodynamic interaction between cyclosporine A and
ciprofloxacin was demonstrated in renal transplant patients, suggesting
that the antibacterial agent may be immunomodulatory, particularly when
T cells were activated (41). The corresponding in vitro
finding, i.e., a cyclosporine A-dependent immunosuppressive effect on
cytokine synthesis counteracted by the quinolone, was observed at
20
µg of ciprofloxacin per ml (29). Taken together, the
collective data suggest that the upregulated IL-2 synthesis observed in
PBLs incubated with low concentrations of ciprofloxacin may reflect a
stress response. However, ciprofloxacin at high concentrations was
required in vitro to clearly demonstrate the relationship.
During treatment of mammalian cells with, for example, cytotoxic drugs
or heavy metals, a stress response is generally triggered, resulting in
induction of several different genes (10, 11). Increased
concentrations of transcriptional regulation factors (27,
30) (Fig. 2) and upregulated c-fos, c-jun,
and cytokine gene transcripts in stimulated eukaryotic cells exposed to
ciprofloxacin suggest that ciprofloxacin might have induced a stress
response similar to a mammalian DNA damage response (genotoxic stress). However, since ciprofloxacin did not increase mutation frequency (DNA
damage) in a shuttle vector plasmid mutation test (3), direct interference with topoisomerase II might be another mechanism by
which ciprofloxacin induced a stress response. Ciprofloxacin at high
concentrations (80 µg/ml) has in fact been shown to interfere with
topoisomerase II in Raji cells when investigated by a neutral elution
technique (2). Interestingly, the topoisomerase II inhibitor
vepeside (VP-16) induces vimentin expression and activates the
GADD153 promoter in the monocytic cell line U-937 (20,
31). In addition, vepeside affects protein kinase C in the same
cell line, causing enhanced AP-1 activity, but without influencing NF-
B binding (23). Inhibition of topoisomerase II in
thymocytes by teniposide (VM-26) leads to superinduction of
c-jun mRNA expression and the c-Jun N-terminal kinase,
resulting in increased AP-1 activity (39). It has also been
shown that teniposide induces the transcription of heat shock genes in
HeLa cells (32). However, despite the fact that vepeside has
been thoroughly documented to induce genotoxic stress, it did not
stimulate IL-2 gene expression in our experimental models
(28). Thus, in addition to triggering a genotoxic response, DNA-damaging agents may directly inhibit topoisomerase II, thus facilitating transcription. This would be another mechanism that accounts for the effects seen in ciprofloxacin-treated cells.
DNA-damaging agents and genotoxic stress may also increase the
stability of certain gene transcripts. Recently it was reported that
photodynamic treatment of HeLa cells resulted in the prolonged half-life of c-jun and c-fos transcripts
(18). UV radiation or methylmethane sulfonate (MMS) also
enhanced mRNA stability for the growth arrest and DNA damage-inducible
(gadd) genes in hamster cells compared to that in untreated
exponentially growing cells (12). Furthermore, Mallardo and
collaborators described an extensive IL-6 and IL-1 mRNA stabilization
in human monocytes incubated with the alkylating agents MMS and
mitomycin (22). In contrast, ciprofloxacin did not appear to
increase the stability of immediate-early mRNAs: no difference in mRNA
turnover was detected in PBLs incubated with or without ciprofloxacin
in the presence of the transcriptional inhibitor actinomycin D (Fig.
6).
Activation of T lymphocytes results in the induction of a number of
genes, such as immediate-early (e.g., c-fos and
c-jun), early (IL-2), and late-response (histone H3) genes
(4). In cells incubated with ciprofloxacin, a time
relationship appeared to exist between the increased c-fos
and c-jun mRNA levels on one hand and the superinduced IL-2
and IFN-
mRNA concentrations on the other (Fig. 1 and 5). In
contrast to ciprofloxacin-treated Jurkat cells that display increased
AP-1 concentrations at 15 min (30), any upregulated AP-1
binding by ciprofloxacin was not detected at earlier time points than
2 h in primary lymphocytes (Fig. 3). Thus, in PBLs, the
upregulated expression of c-fos and c-jun mRNAs
was not preceded by increased AP-1 activity. The mRNAs of at least six
different Fos and Jun proteins included in the AP-1 protein complex are
detected in stimulated T cells (13). Interestingly, in our
highly purified CD4+ T cells activated with PHA and PMA,
the induced AP-1 detected at 2 and 3 h of activation mainly
consisted of the proteins FosB, JunB, and JunD (Fig. 4). The
immediate-early genes encoding members of the Jun and Fos families are
tightly controlled by transcription factors other than AP-1. The
regulation of c-fos is mediated by factors binding to a
cyclic AMP-responsive element (CRE), Sis-inducible enhancer (SIE), and,
finally, a serum-response element (SRE) (see reference
16 for a review). Numerous transcriptional
regulation factors, including CRE-binding proteins and the signal
transducer and activator of transcription factors, including
CRE-binding proteins and the signal transducer and activator of
transcription (STAT) group, bind to the c-fos enhancer and
promoter region. In contrast, c-jun is induced via a
tetradecanoyl phorbol acetate-responsive element (TRE), which has been
proposed to be recognized by c-Jun-activating transcription factor 2 (ATF2) heterodimers in addition to other presently unknown factors.
Taken together, ciprofloxacin induced transcripts consisting of members
of the Jun and Fos families, resulting in dimeric protein complexes
that in turn constituted AP-1.
Depending on the composition of the AP-1 dimer, different sequence
elements are preferentially recognized. Two AP-1 binding sequences
exist in the promoter of the T-cell cytokine IL-2 (4, 6). In
contrast to a less important distal AP-1 site, the proximal AP-1
sequence is crucial for IL-2 gene induction and represents a major site
of protein kinase C responsiveness (14). Deletion of the
proximal site diminishes the IL-2 promoter activity by approximately
75%, compared to that of the wild type (6). We investigated
the effect of ciprofloxacin on IL-2 promoter induction in a
well-defined murine system by using different constructs consisting of
mutated IL-2 enhancer and promoter regions (27). No
upregulated CAT conversion was found with an IL-2 promoter construct
lacking the proximal AP-1 site in the presence of ciprofloxacin (25a). In contrast, in experiments with IL-2 promoter
constructs lacking the NF-AT-1 or Oct-1/OAP40 binding
sequences, ciprofloxacin increased CAT activity regardless of the
mutated sequence compared to that in drug-free controls. Moreover, in
the present study, it was shown that ciprofloxacin increased expression
for both constructs MT-CAT-SV and IL-2-CAT-SV containing the promoters
metallothionein and IL-2, respectively (Fig. 2). To reach the detection
limit for CAT in primary lymphocytes, we had to include the SV40
enhancer. It is well known that AP-1 is crucial for the activity of the
SV40 enhancer and the IL-2 promoter (6, 25). In contrast,
AP-1 seems to be less important for the induction of the
metallothioneins (24). When the AP-1 site was mutated in the
human metallothionein promoter, the low basal activity disappeared,
while the metallothionein gene still could be induced by
Zn2+ (21). Unpublished observations from our
laboratory reveal that in contrast to an intact promoter, the
metallothionein promoter with a mutated AP-1 site (21) was
not enhanced by ciprofloxacin in stimulated murine EL-4 cells. Most
likely the ciprofloxacin-dependent upregulation of MT-CAT-SV activity
in PBLs was not caused by the non-AP-1-related transcription factors
(24) but was due to a combination of the AP-1 binding
sequences in the metallothionein promoter and the SV40 enhancer
element. Ciprofloxacin appeared to mainly interfere with AP-1 activity
when transcriptional activity was examined with CAT constructs.
In conclusion, an association between stress response and cytokine
superinduction triggered by ciprofloxacin has been described in the
present communication. Several gene transcripts included in the c-Fos
and c-Jun families in addition to most T-cell cytokines (30)
were augmented in primary lymphocytes exposed to ciprofloxacin. Moreover, AP-1 binding activity was increased in ciprofloxacin-treated PBLs, which is a commonly described phenomenon during mammalian stress.
Despite the available evidence of immunomodulatory effects of
ciprofloxacin in vivo (36, 41), the clinical significance of
our findings warrants further studies.
 |
ACKNOWLEDGMENTS |
We thank Michael Karin, Carsten Jonat, and Tullia Lindsten for
providing us with plasmids.
This investigation was supported by grants from the Anna and Edwin
Berger Foundation, the Greta and Johan Kock Foundation, the Cancer
Foundation at University Hospital MAS, the Swedish Medical Research
Council, and the Österlund Foundation.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medical Microbiology, Lund University, Malmö University Hospital,
S-205 02 Malmö, Sweden. Phone: 46-40-331340. Fax: 46-40-336234. E-mail: kristian.riesbeck{at}mikrobiol.mas.lu.se.
 |
REFERENCES |
| 1.
|
Boise, L. H.,
B. Petryniak,
X. Mao,
C. H. June,
C.-Y. Wang,
T. Lindsten,
R. Bravo,
K. Kovary,
J. M. Leiden, and C. B. Thompson.
1993.
The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB.
Mol. Cell. Biol.
13:1911-1919[Abstract/Free Full Text].
|
| 2.
|
Bredberg, A.,
M. Brant, and M. Jaszyk.
1991.
Ciprofloxacin-induced inhibition of topoisomerase II in human lymphoblastoid cells.
Antimicrob. Agents Chemother.
35:448-450[Abstract/Free Full Text].
|
| 3.
|
Bredberg, A.,
M. Brant,
K. Riesbeck,
Y. Azou, and A. Forsgren.
1989.
4-Quinolone antibiotics: positive genotoxic screening tests despite an apparent lack of mutation induction.
Mutat. Res.
211:171-181[Medline].
|
| 4.
|
Crabtree, G. R., and N. A. Clipstone.
1994.
Signal transmission between the plasma membrane and the nucleus of T-lymphocytes.
Annu. Rev. Biochem.
63:1045-1083[Medline].
|
| 5.
|
Drlica, K., and X. Zhao.
1997.
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Microbiol. Mol. Biol. Rev.
61:377-392[Abstract].
|
| 6.
|
Durand, D. B.,
J.-P. Shaw,
M. R. Bush,
R. E. Replogle,
R. Balagaje, and G. R. Crabtree.
1988.
Characterization of antigen receptor response elements within the interleukin-2 enhancer.
Mol. Cell. Biol.
8:1715-1724[Abstract/Free Full Text].
|
| 7.
|
Engelberg, D.,
C. Klein,
H. Martinetto,
K. Struhl, and M. Karin.
1994.
The UV response involving the Ras signaling pathway and AP-1 transcription factors is conserved between yeast and mammals.
Cell
77:381-390[Medline].
|
| 8.
|
Forsgren, A.,
S. F. Schlossman, and T. F. Tedder.
1987.
4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro.
Antimicrob. Agents. Chemother.
31:768-773[Abstract/Free Full Text].
|
| 9.
|
Hattori, K.,
P. Angel,
M. M. LeBeau, and M. Karin.
1988.
Structure and chromosomal localization of the functional intronless human protooncogene JUN.
Proc. Natl. Acad. Sci. USA
85:9148-9152[Abstract/Free Full Text].
|
| 10.
|
Herrlich, P.,
H. Ponta, and H. J. Rahmsdorf.
1992.
DNA damage-induced gene expression: signal transduction and relation to growth factor signaling.
Rev. Physiol. Biochem. Pharmacol.
119:187-223[Medline].
|
| 11.
|
Holbrook, N. J.,
Y. Liu, and A. J. Fornace, Jr.
1996.
Signaling events controlling the molecular response to genotoxic stress, p. 273-288.
In
U. Feige, R. I. Morimoto, I. Yahara, and B. Polla (ed.), Stress-inducible cellular responses 1996. Birkhäuser Verlag, Basel, Switzerland.
|
| 12.
|
Jackman, J.,
I. Alamo, Jr., and A. J. Fornace, Jr.
1994.
Genotoxic stress confers preferential and coordinate messenger RNA stability on the five gadd genes.
Cancer Res.
54:5656-5662[Abstract/Free Full Text].
|
| 13.
|
Jain, J.,
V. E. Valge-Archer, and A. Rao.
1992.
Analysis of the AP-1 sites in the IL-2 promoter.
J. Immunol.
148:1240-1250[Abstract].
|
| 14.
|
Jain, J.,
V. E. Valge-Archer,
A. J. Sinskey, and A. Rao.
1992.
The AP-1 site at 150 bp, but not the NF- B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.
J. Exp. Med.
175:853-862[Abstract/Free Full Text].
|
| 15.
|
Kägi, J. H.
1991.
Overview of metallothionein.
Methods Enzymol.
205:613-626[Medline].
|
| 16.
|
Karin, M.,
L. Zheng-Gang, and E. Zandi.
1997.
AP-1 function and regulation.
Curr. Opin. Cell Biol.
9:240-246[Medline].
|
| 17.
|
Kharabanda, S.,
Z.-M. Yuan,
R. Weichselbaum, and D. Kufe.
1997.
Functional role for the c-Abl protein tyrosine kinase in the cellular response to genotoxic stress.
Biochim. Biophys. Acta
1333:O1-O7[Medline].
|
| 18.
|
Kick, G.,
G. Messer,
G. Plewig,
P. Kind, and A. E. Goetz.
1996.
Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy.
Br. J. Cancer
74:30-36[Medline].
|
| 19.
|
Kletter, Y.,
I. Riklis,
I. Shalit, and I. Fabian.
1991.
Enhanced repopulation of murine hematopoietic organs in sublethally irradiated mice after treatment with ciprofloxacin.
Blood
78:1685-1691[Abstract/Free Full Text].
|
| 20.
|
Luethy, J. D., and N. J. Holbrook.
1992.
Activation of the gadd153 promoter by genotoxic agents: a rapid specific response to DNA damage.
Cancer Res.
52:5-10[Abstract/Free Full Text].
|
| 21.
|
Makarov, S. S.,
C. Jonat, and S. Haskill.
1994.
Hyperinducible human metallothionein promoter with a low level basal activity.
Nucleic Acids Res.
22:1504-1505[Free Full Text].
|
| 22.
|
Mallardo, M.,
V. Giordano,
E. Dragonetti,
G. Scala, and I. Quinto.
1994.
DNA damaging agents increase the stability of interleukin-1 alpha, interleukin-1 beta, and interleukin-6 transcripts and the production of the relative proteins.
J. Biol. Chem.
269:14899-14904[Abstract/Free Full Text].
|
| 23.
|
Perez, C.,
N. E. Vilaboa,
L. Garcia-Bermejo,
E. de-Blas,
A. M. Creighton, and P. Aller.
1997.
Differentiation of U-937 promonocytic cells by etoposide and ICRF-193, two antitumour DNA topoisomerase inhibitors with different mechanisms of action.
J. Cell Sci.
110:337-343[Abstract].
|
| 24.
|
Radtke, F.,
R. Heuchel,
O. Georgiev,
M. Hergersberg,
M. Gariglio,
Z. Dembic, and W. Schaffner.
1993.
Cloned transcription factor MTF-1 activates the mouse metallothionein I promoter.
EMBO J.
12:1355-1362[Medline].
|
| 25.
|
Rahmsdorf, H. J., and P. Herrlich.
1990.
Regulation of gene expression by tumor promoters.
Pharmacol. Ther.
48:157-188[Medline].
|
| 25a.
| Riesbeck, K. Unpublished observations.
|
| 26.
|
Riesbeck, K.,
J. Andersson,
M. Gullberg, and A. Forsgren.
1989.
Fluorinated 4-quinolones induce hyperproduction of interleukin 2.
Proc. Natl. Acad. Sci. USA
86:2809-2813[Abstract/Free Full Text].
|
| 27.
|
Riesbeck, K., and A. Forsgren.
1994.
Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin.
Immunopharmacology
27:155-164[Medline].
|
| 28.
|
Riesbeck, K., and A. Forsgren.
1995.
CP-115,953 stimulates cytokine production by lymphocytes.
Antimicrob. Agents Chemother.
39:476-483[Abstract/Free Full Text].
|
| 29.
|
Riesbeck, K.,
M. Gullberg, and A. Forsgren.
1994.
Evidence that the antibiotic ciprofloxacin counteracts cyclosporine-dependent suppression of cytokine production.
Transplantation
57:267-272[Medline].
|
| 30.
|
Riesbeck, K.,
M. Sigvardsson,
T. Leanderson, and A. Forsgren.
1994.
Superinduction of cytokine gene transcription by ciprofloxacin.
J. Immunol.
153:343-352[Abstract].
|
| 31.
|
Rius, C.,
A. R. Zorilla,
C. Cabans,
F. Mata,
C. Bernabeu, and P. Aller.
1991.
Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression.
Mol. Pharmacol.
39:442-448[Abstract].
|
| 32.
|
Schaak, J.,
P. Schedl, and T. Schenk.
1990.
Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.
Nucleic Acids Res.
18:1499-1508[Abstract/Free Full Text].
|
| 33.
|
Schöler, H. R.,
A. K. Hatzopoulos,
R. Balling,
N. Suzuki, and P. Gruss.
1989.
A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor.
EMBO J.
8:2543-2550[Medline].
|
| 34.
|
Schultze-Osthoff, K.,
M. K. A. Bauer,
M. Vogt, and S. Wesselborg.
1997.
Oxidative stress and signal transduction.
Int. J. Vitam. Nutr. Res.
67:336-342[Medline].
|
| 35.
|
Schwartz, M. A.,
J. S. Lazo,
J. C. Yalowich,
I. Reynolds,
V. E. Kagan,
V. Tyurin,
Y.-M. Kim,
S. C. Watkins, and B. R. Pitt.
1994.
Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity.
J. Biol. Chem.
269:15238-15243[Abstract/Free Full Text].
|
| 36.
|
Shalit, I.,
Y. Kletter,
K. Weiss,
T. Gruss, and I. Fabian.
1997.
Enhanced hematopoiesis in sublethally irradiated mice treated with various quinolones.
Eur. J. Haematol.
58:92-98[Medline].
|
| 37.
|
Smith, M. L., and A. J. Fornace, Jr.
1996.
Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis.
Mutat. Res.
340:109-124[Medline].
|
| 38.
|
Stünkel, K. G. E.,
G. Hewlett, and H. J. Zeiler.
1991.
Ciprofloxacin enhances T cell function by modulating interleukin activities.
Clin. Exp. Immunol.
86:525-531[Medline].
|
| 39.
|
Testolin, L.,
C. Carson,
Y. Wang,
P. R. Walker,
U. Armato, and M. Sikorska.
1997.
Jun and JNK kinase are activated in thymocytes in response to VM26 and radiation but not glucocorticoids.
Exp. Cell Res.
230:220-232[Medline].
|
| 40.
|
Walker, G. C.
1984.
Mutagenesis and inducible responses to deoxyribonucleic acid damage in Escherichia coli.
Microbiol. Rev.
48:60-93[Free Full Text].
|
| 41.
|
Wrishko, R. E.,
M. Levine,
D. R. N. Primmett,
S. Kim,
N. Partovi,
S. Lewis,
D. Landsberg, and P. A. Keown.
1997.
Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients.
Transplantation
64:996-999[Medline].
|
| 42.
|
Zehavi-Willner, T., and I. Shalit.
1989.
Enhancement of interleukin-2 production in human lymphocytes by two new quinolone derivatives.
Lymphokine Res.
3:35-46.
|
Antimicrobial Agents and Chemotherapy, August 1998, p. 1923-1930, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Choi, J.-H., Song, M.-J., Kim, S.-H., Choi, S.-M., Lee, D.-G., Yoo, J.-H., Shin, W.-S.
(2003). Effect of Moxifloxacin on Production of Proinflammatory Cytokines from Human Peripheral Blood Mononuclear Cells. Antimicrob. Agents Chemother.
47: 3704-3707
[Abstract]
[Full Text]
-
Corps, A. N., Curry, V. A., Harrall, R. L., Dutt, D., Hazleman, B. L., Riley, G. P.
(2003). Ciprofloxacin reduces the stimulation of prostaglandin E2 output by interleukin-1{beta} in human tendon-derived cells. Rheumatology (Oxford)
42: 1306-1310
[Abstract]
[Full Text]
-
Eriksson, E., Forsgren, A., Riesbeck, K.
(2003). Several gene programs are induced in ciprofloxacin-treated human lymphocytes as revealed by microarray analysis. J. Leukoc. Biol.
74: 456-463
[Abstract]
[Full Text]
-
Purswani, M. U., Eckert, S. J., Arora, H. K., Noel, G. J.
(2002). Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. J Antimicrob Chemother
50: 51-58
[Abstract]
[Full Text]
-
Matsunaga, K., Klein, T. W., Friedman, H., Yamamoto, Y.
(2001). Legionella pneumophila Replication in Macrophages Inhibited by Selective Immunomodulatory Effects on Cytokine Formation by Epigallocatechin Gallate, a Major Form of Tea Catechins. Infect. Immun.
69: 3947-3953
[Abstract]
[Full Text]
-
Britton, K. E., Wareham, D., Solanki, K. K., Das, S. S., Welling, M. M., Nibbering, P. H., Paulusma-Annema, A., Hiemstra, P. S., Pauwels, E. K.J., Calame, W.
(2000). Imaging of Bacterial Infections with 99mTc-Labeled Human Neutrophil Peptide-1. JNM
41: 2099-2102
[Full Text]
-
Labro, M.-T.
(2000). Interference of Antibacterial Agents with Phagocyte Functions: Immunomodulation or ""Immuno-Fairy Tales""?. Clin. Microbiol. Rev.
13: 615-650
[Abstract]
[Full Text]